Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8WWH5

UPID:
TRUB1_HUMAN

ALTERNATIVE NAMES:
TruB pseudouridine synthase homolog 1; tRNA pseudouridine 55 synthase TRUB1

ALTERNATIVE UPACC:
Q8WWH5; B2R716; Q53ES2

BACKGROUND:
The enzyme Pseudouridylate synthase TRUB1, with alternative names TruB pseudouridine synthase homolog 1 and tRNA pseudouridine 55 synthase TRUB1, is crucial for the pseudouridylation process of mRNAs and tRNAs. It mediates the modification of mRNAs containing a specific consensus sequence and plays a significant role in the pseudouridylation of certain tRNAs, including the conversion of uracil-55 to pseudouridine(55). TRUB1 also has a non-enzymatic role in the maturation of pri-let-7 microRNAs, by preventing the binding of LIN28 and enhancing the interaction with the microprocessor DGCR8, which is essential for miRNA processing.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Pseudouridylate synthase TRUB1 could lead to the development of novel therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.